​Radient Announces Upsize of its Previously Announced Bought Deal Offering to $21.6M and Concurrent Private Placement for Up to an Additional $15M

Spotlight Companies  |

Radient Technologies Inc.  (RTI:CA)is pleased to announce that it has entered into an underwriting agreement with a syndicate of underwriters led by Canaccord Genuity Corp. (the "Lead Underwriter") and including GMP Securities L.P. and Laurentian Bank Securities Inc. (together with the Lead Underwriter, the "Underwriters") to increase the size of the previously announced bought deal offering to an offering of 18,000,000 units (the "Units") of the Company at a price of $1.20 per Unit (the "Offering Price") for aggregate gross proceeds of approximately $21,600,000 (the "Upsized Offering"). The Underwriters have been granted the option (the "Over-Allotment Option") to purchase up to an additional 2,700,000 Units, exercisable in whole or in part, at any time up to 30 days following the closing of the Upsized Offering.

As previously announced, each Unit will consist of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant shall be exercisable to acquire one additional common share (a "Warrant Share") of the Company for a period of two years from the closing date of the Upsized Offering at an exercise price of $1.50 per Warrant Share. If, at any time prior to the expiry date of the Warrants, the volume weighted average price of Radient's common shares exceeds $2.25 for 20 consecutive trading days, the Company may deliver a notice to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice (the "Accelerated Exercise Period"). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period. The Warrants will not be listed for trading on the TSXV or any other public exchange.

The Units comprising the Upsized Offering will be offered by way of short form prospectus in Alberta, British Columbia and Ontario. The proceeds of the Upsized Offering and the Private Placement (described below) will be used to upgrade the Company's main Edmonton extraction line for dedicated hemp extraction and purification, for additional capacity in North America and/or Europe and for general corporate and working capital purposes.

In connection with the Upsized Offering, the Company has agreed to pay to the Underwriters a cash commission equal to 6% of the gross proceeds from the Upsized Offering (the "Underwriters' Fee"). In addition to the Underwriters' Fee, the Company has agreed to issue to the Underwriters compensation options (the "Compensation Options"), exercisable at the Offering Price to purchase such number of Units as is equal to 6% of the aggregate number of Units sold.



In addition to the Upsized Offering, the Company is arranging a concurrent private placement of Units for additional aggregate gross proceeds of up to $15 million (the "Private Placement"). In connection with the Private Placement, the Company may pay commission to certain finders (the "Finders") in cash, Units and/or Compensation Options, subject to the limitations set out in TSXV Policy 5.1 - Loans, Loan Bonuses, Finder's Fees and Commissions. The Company may increase the size of the Private Placement to $25 million with the consent of the Lead Underwriter.

Closing of the Private Placement is subject to receipt of applicable regulatory approvals including approval of the TSX Venture Exchange. Securities issued under the Private Placement will be subject to a four month hold period which will expire four months plus a day from the date of closing of the Private Placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state of the United States in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the 1933 Act, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as such terms are defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements.

About Radient

Radient extracts natural compounds from a range of biological materials using microwave assisted processing ("MAP™"), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health and personal care markets. Since 2016, Radient has expanded its offerings to enter the cannabinoids market utilizing its MAP™ platform to process and extract cannabinoids including cannabidiol and tetrahydrocannabinol from cannabis biomass.

The Company, having received its Dealer's License from Health Canada's Office of Controlled Substances for its Research & Development Laboratory located at 8223 Roper Road in February 2018, is in the review phase of its application to the Office of Medical Cannabis for the ACMPR Production License (the "ACMPR License") for its manufacturing facility located at 4035 101 St NW in Edmonton. Approval of the ACMPR License is dependent upon, among other things, security upgrades included in the Company's previously announced plant expansion and optimization project, scheduled for completion in the 2nd half of 2018. The Company's application to the Office of Controlled Substances for a Dealer's License for its manufacturing facility is also currently under review.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
RTI:CA Radient Technologies Inc. 1.09 0.03 2.83 482,117

Comments

Emerging Growth

Global Cannabis

Global Cannabis Applications Corp is engaged in the design, acquire data and develop applications for smartphones and tablets. The company offer Citizen Green platform, an end to end infrastructure to…